BPA Biosante Pharmaceuticals

Biosante Pharmaceuticals, Inc. (AMEX: BPA) will present at the following forum: -0- *T What: Informed Investors Biotechnology / Healthcare / Pharmaceutical Investor Forum When: June 15, 2005 @ 1:25 PM Eastern Time Sponsors: Barron's, The Wall Street Journal, The American Stock Exchange and Business Wire Keynote Presentations: Lynn Sutherland, M.S., M.B.A. - President, Sutherland Consulting Dr. Navdeep Jaikaria, Senior Biotechnology Analyst, Rodman & Renshaw, LLC Where: The Princeton Club of New York, 15 West 43rd Street., New York City, NY 10036 How to attend: Pre-registration is necessary. To register, contact Cary Loeser, cloeser@wilink.com, or 804-327-3407. You may also call Customer Service at 888-301-6618, or register at the following link: http://www.informedinvestors.com/CustomEvent/89559/index.asp If you are unable to attend the live event, the forum will be available via webcast at http://www.informedinvestors.com/CustomEvent/89559/index.asp Contact: Phillip Donenberg, Chief Financial Officer, (847)478-0500, donenber@biosantepharma.com *T BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Bio-E-Gel(TM) (bioidentical estradiol gel) for the treatment of women with menopausal symptoms, and LibiGel(TM) (bioidentical testosterone gel) for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The company also is developing its calcium phosphate nanotechnology (CAP) for novel vaccines, including biodefense vaccines for toxins such as anthrax and ricin, and drug delivery systems. Additional information is available online at www.biosantepharma.com.